These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24451964)

  • 21. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma.
    Usakova V; Sevcikova K; Usak J; Bartosova Z; Mikulova M; Spanik S
    Neoplasma; 2013; 60(1):83-91. PubMed ID: 23067221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
    Hurwitz HI; Tebbutt NC; Kabbinavar F; Giantonio BJ; Guan ZZ; Mitchell L; Waterkamp D; Tabernero J
    Oncologist; 2013; 18(9):1004-12. PubMed ID: 23881988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
    Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
    Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis.
    Gampenrieder SP; Romeder F; Muß C; Pircher M; Ressler S; Rinnerthaler G; Bartsch R; Sattlberger C; Mlineritsch B; Greil R
    Anticancer Res; 2014 Jan; 34(1):227-33. PubMed ID: 24403467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
    J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.
    Jang HJ; Kim BJ; Kim JH; Kim HS
    Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Baraniskin A; Buchberger B; Pox C; Graeven U; Holch JW; Schmiegel W; Heinemann V
    Eur J Cancer; 2019 Jan; 106():37-44. PubMed ID: 30476731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
    Li J; Zhou L; Chen X; Ba Y
    Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis.
    Qu CY; Zheng Y; Zhou M; Zhang Y; Shen F; Cao J; Xu LM
    World J Gastroenterol; 2015 Apr; 21(16):5072-80. PubMed ID: 25945023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study.
    Moscetti L; Nelli F; Fabbri MA; Sperduti I; Alesini D; Cortesi E; Gemma D; Gamucci T; Grande R; Pavese I; Franco D; Ruggeri EM
    Invest New Drugs; 2013 Aug; 31(4):1035-43. PubMed ID: 23417697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date.
    Zhang G; Zhou X; Lin C
    Int J Clin Exp Med; 2015; 8(1):1434-45. PubMed ID: 25785152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis.
    Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J
    Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.